

Contents

Introduction

329 Challenging Dogmas in IBD

D'Haens, G. (Amsterdam)

IBD Is a Disorder of Defective Autophagy and Innate Immunity

330 Evidence from Genetics for a Role of Autophagy and Innate Immunity in IBD Pathogenesis

Parkes, M. (Cambridge)

334 Commensal-Innate Immune Miscommunication in IBD Pathogenesis

Cario, E. (Essen)

341 Endoplasmic Reticulum Stress and Inflammation

Adolph, T.-E.; Niederreiter, L. (Cambridge); Blumberg, R.S. (Boston, Mass.); Kaser, A. (Cambridge)

No Bacteria, No IBD

347 Lessons from Diversion Studies and Antibacterial Interventions

Flanagan, P.K.; Campbell, B.J.; Rhodes, J.M. (Liverpool)

351 Bacteriology in the Etiopathogenesis of Pouchitis

Shen, B. (Cleveland, Ohio)

358 The Role of Anti(myco)bacterial Interventions in the Management of IBD: Is There Evidence at All?

Pineton de Chambrun, G.P. (Lille); Torres, J. (New York, N.Y.); Darfeuille-Michaud, A. (Clermont-Ferrand); Colombel, J.-F. (Lille/New York, N.Y.)

Steroids Are Useful for the Management of IBD

368 Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects?

De Cassan, C.; Fiorino, G.; Danese, S. (Milan)

Early and Late Crohn's Disease Are Distinct Entities

376 Epidemiology of the Transition from Early to Late Crohn's Disease

Louis, E. (Liège)

380 Markers That Differentiate Early from Late IBD

Huang, C.; Kugathasan, S. (Atlanta, Ga.)

Innovative Treatments Will Offer a Better Outcome for Patients with IBD

383 Biologic Therapies: Lessons from Multiple Sclerosis

Ghosh, S. (Calgary, Alta.)

387 Current Status of Mesenchymal Stem Cell Therapy and Bone Marrow Transplantation in IBD

Ricart, E. (Barcelona)

392 Reprogramming the Immune System in IBD

MacDonald, T.T.; Vossenkaemper, A. (London); Fantini, M.; Monteleone, G. (Rome)

Patient-Tailored Therapies Are Superior to Algorithmic Approaches in IBD

396 How to Guide Therapeutic Decisions in a Patient-Tailored Approach to Treatment of IBD?

Rutgeerts, P. (Leuven)

400 Treat the Patient or Treat the Disease?

Hanauer, S.B.; Kirsner, J.B. (Chicago, Ill.)

Immunosuppression Puts IBD Patients at Risk for Severe Complications

404 Combined Immunosuppression Is More Dangerous than Monotherapy: What Is Fact and What Is Fiction?

Schölmerich, J. (Frankfurt)

408 Prevention and Management of Infectious Complications in IBD

Rahier, J.-F. (Yvoir)

415 Immunosuppression-Related Lymphomas and Cancers in IBD: How Can They Be Prevented?

Beaugerie, L. (Paris)

420 How to Manage IBD in Patients with Infections or Malignancies?

Kohn, A.; Meddi, P. (Roma)

Leaving the Dogmas Behind and Looking into the Future

425 Towards a Novel Molecular Classification of IBD

Vermeire, S. (Leuven)

428 Towards a 'Cure' for IBD

Fiocchi, C. (Cleveland, Ohio)

434 Falk Symposium Series

437 Author Index

438 Subject Index